Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study
Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study.|
- Improvement of Quality of life in patients with hyperhidrosis with the use of oxybutynin [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]Using a Quality of life protocol we will study if patients with hyperhidrosis using oxybutynin have an improvement in their quality of life
- The use of oxybutynin diminishes hyperhidrosis [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]if the use of oxybutynin diminishes hyperhidrosis
|Study Start Date:||December 2010|
|Study Completion Date:||March 2011|
|Primary Completion Date:||February 2011 (Final data collection date for primary outcome measure)|
patients will receive in the end of the treatment, 10 mg of oxybutynin a day
5 mg every 12 hours for 6 weeks
Placebo Comparator: Placebo
placebo twice a day for 42 days.
Introduction: Video-assisted thoracic sympathectomy (VATS) provides excellent resolution of palmar and axillary hyperhidrosis but is associated with compensatory hyperhidrosis. Low doses of Oxybutynin can be used to treat palmar hyperhidrosis with fewer side effects.
Purpose: The objective of this study is to evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses comparing to placebo for treating palmar hyperhidrosis.
Methods: This is a prospective, randomized and controlled study. From December 2010 to february 2011, 50 consecutive patients with palmar hyperhidrosis were treated with oxybutynin or placebo. Data were collected from 50 patients, and 5 (10,0%) patients were lost to follow-up. During the first week, patients received 2.5 mg of oxybutynin once a day in the evening. From the 8th to the 42nd day, they received 2.5 mg twice a day, and from the 43rd day to the end of the 12th week, they received 5 mg twice a day. All of the patients underwent 2 evaluations: before and after (12 weeks) the oxybutynin treatment, using a clinical questionnaire; and a clinical protocol for quality of life (QOL).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01310712
|Hospital das Clinicas da FMUSP|
|Sao Paulo, Brazil, 05679040|
|Principal Investigator:||WOLOSKER NELSON, Md, PhD||University of Sao Paulo|